Erasca, Inc. Form 10-Q Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. The filing covers the quarter and nine months ended September 30, 2022, and was filed November 9, 2022. The company had no approved products and generated no product revenue.
The pipeline included 11 disclosed programs, including clinical-stage ERAS-007, ERAS-601 and ERAS-801, plus preclinical and discovery programs. Management expected four product candidates to be in the clinic in 2023 and additional IND filings every 12–18 months through 2026.
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $28.2 million | $83.1 million |
| General and administrative expense | $8.8 million | $24.3 million |
| Total operating expenses | $37.0 million | $109.4 million |
| Net loss | $35.5 million | $107.6 million |
| Net loss per share | $0.29 | $0.90 |
| Net cash used in operating activities | Not separately provided | $76.9 million |
There is no meaningful revenue or operating margin because the company remains pre-commercial and loss-making. The accumulated deficit was $345.7 million at September 30, 2022.
- Cash and cash equivalents: $219.3 million.
- Short-term marketable securities: $136.7 million.
- Long-term marketable securities: $9.6 million.
- Total cash, cash equivalents and marketable securities: approximately $365.5 million.
- Total assets: $446.4 million; total liabilities: $81.1 million; stockholders’ equity: $365.3 million.
- Debt: the filing does not report outstanding debt; liabilities primarily consisted of operating lease liabilities, including $54.5 million of current and long-term operating lease liabilities.
- Net cash used in investing activities was $66.2 million, including $49.5 million of net purchases of marketable securities, $13.7 million of property and equipment purchases and a $2.0 million equity investment.
- Net cash provided by financing activities was $1.9 million, primarily from option exercises and the employee stock purchase plan.
Material changes versus the prior comparable period
- Third-quarter net loss improved to $35.5 million from $46.1 million, primarily because the prior-year period included a $17.5 million common-stock contribution to the Erasca Foundation and $1.7 million of in-process research and development expense.
- Nine-month net loss increased to $107.6 million from $92.3 million as research and development and general and administrative spending expanded.
- Research and development expense increased 41% in the third quarter and 67% for the nine-month period, reflecting higher clinical, preclinical, discovery, facilities, personnel, outsourced-services and stock-based compensation costs.
- General and administrative expense increased 27% in the third quarter and 55% for the nine-month period, driven mainly by stock-based compensation, legal and accounting fees, insurance and facility costs.
- Operating cash burn increased to $76.9 million for the first nine months from $57.1 million in the prior-year period. The prior-year period benefited from noncash items related to the IPO and Foundation contribution.
- Cash, cash equivalents and restricted cash declined by $141.2 million during the first nine months, compared with a $380.5 million increase in the prior-year period, which included IPO and preferred-stock proceeds.
- Facilities expanded materially. Operating lease assets increased to $41.1 million from $17.4 million at year-end 2021, and property and equipment increased to $24.9 million from $16.0 million.
Guidance, outlook, risks and unusual items
- Management estimated that cash, cash equivalents and marketable securities would fund operations into the second half of 2024, while also stating that the estimate is subject to substantial uncertainty.
- The company expects operating expenses and losses to increase substantially as clinical trials, preclinical work, manufacturing, staffing, intellectual-property activities and public-company costs expand.
- An at-the-market equity facility permits sales of up to $200 million of common stock, with commissions of up to 3% of gross proceeds. No shares had been sold under the facility as of September 30, 2022.
- The company expects to require additional capital through equity or debt financings, collaborations, licenses or other arrangements. Failure to obtain financing could delay, reduce or terminate development programs and may dilute existing stockholders.
- The company recorded a $2.2 million employee retention credit in the third quarter, reducing research and development and general and administrative expenses.
- Clinical development remains subject to efficacy, safety, enrollment, regulatory, manufacturing and supply-chain risks. The company relies on third parties for manufacturing, packaging, storage, distribution, clinical research and certain combination agents.
- License and acquisition agreements create potential future development, regulatory and commercial milestone obligations, royalties and, in certain cases, additional equity issuance obligations. No material contingencies were accrued as of September 30, 2022.
- The company reported no material legal proceedings, no material changes to previously disclosed risk factors and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective at the reasonable assurance level.
Most important facts for investors to verify
- Confirm clinical-trial enrollment, safety, efficacy and timing of planned HERKULES, FLAGSHP-1 and THUNDERBBOLT-1 data readouts.
- Assess whether the projected cash runway to the second half of 2024 remains achievable given the rising quarterly cash burn and planned pipeline expansion.
- Monitor use of the $200 million at-the-market facility and the resulting potential equity dilution.
- Review future milestone, royalty and equity issuance obligations under the Asana, NiKang, Katmai, LifeArc, UCSF and other agreements.
- Evaluate the financial impact and operational risks associated with the company’s expanded San Diego and South San Francisco leases, including approximately $88.0 million of future minimum lease payments before interest and tenant-improvement adjustments.
- Verify the distinction between approximately $355.9 million of cash, cash equivalents and short-term marketable securities disclosed in the notes and approximately $365.5 million including long-term marketable securities.